By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has signed an agreement with BioMarin Pharmaceutical to perform BRCA1 and BRCA 2 mutation testing for the drug firm's PARP inhibitor drug candidate, Myriad said after the close of the market on Wednesday.

The testing will be done on patients enrolled in BioMarin's Phase I and Phase II clinical study of its PARP inhibitor called BMN 673 for patients with advanced or recurrent tumors.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.